Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$1.70 pre mkt open
Why do you think I bash
Currently up 100%
PUMPED right back to .65+. Every stock you bash I buy and make 50%+ on. Lmao
Really! Finally breaks out over .5 and then slammed to right back where we started smh…. Damn short interest
DUMPED right back down to .40
AEMD as of close of business May 23 2024 AEMD only has 9,229,725 of outstanding shares.
DUMPED back to low .40zzz after it almost broke out…
Is this one of those 100-baggers? .......Thanks!!!
AEMD… 3 daily gap dowNs, way below the lower keltner line here… GidDy uP AEMD
https://schrts.co/TxGGNVAi
AEMD creeping uP after hours… Still Cheapies…
Even lower now.
Will it grow legs after 9:30
Most med techs don’t
Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma
HAS AMED R/S YET ?????
AEMD
Aethlon Medical Inc
0.331
-0.0156 (-4.50%)
Volume: 77,709
Day Range: 0.3213 - 0.3466
Last Trade Time: 7:52:36 PM EDT
Ahhh the ole R/S to purge the investors. I kissed this one goodbye a long time ago. This will be my 3rd R/S. Nothing left of this garbage I've had stinkin up my portfolio since 2014. This is what they do in pennyland. Per the proxy: Reverse stock split of our common stock at a ratio in the range of 1-for-8 to 1-for-12, with such ratio to be determined in the discretion of our Board of Directors and with such reverse stock split to be effected at such time and date as determined by our Board of Directors in its sole discretion.
AEMD
Aethlon Medical Inc
0.436
0.0016 (0.37%)
Volume: 87,927
Day Range: 0.4201 - 0.4599
Bid: 0.4359
Ask: 0.4499
Last Trade Time: 7:30:44 PM EDT
Total Trades: 258
Gathering steam. Yes, $AEMD$
yes AEMD
Aethlon Medical Inc
0.4344
-0.0159 (-3.53%)
Volume: 217,584
Day Range: 0.432 - 0.46
Bid: 0.4562
Ask: 0.458
Last Trade Time: 4:36:56 PM EDT
Total Trades: 384
AEMD
Aethlon Medical Inc
0.418
-0.007 (-1.65%)
Volume: 761,142
Day Range: 0.40 - 0.4375
Last Trade Time: 7:54:26 PM EDT
AEMD
Aethlon Medical Inc
0.418
-0.007 (-1.65%)
Volume: 761,142
Day Range: 0.40 - 0.4375
Bid: 0.417
Ask: 0.4349
Last Trade Time: 7:54:26 PM EDT
Total Trades: 1,490
close .425 according to my fidlelity.
bought a few more a tad higher than close. Nice volume. Glad though I added a few days ago as well.
yes, creeping <> AEMD
Aethlon Medical Inc
0.4101
0.0701 (20.62%)
Volume: 8,100,795
Day Range: 0.38 - 0.50
Bid: 0.4101
Ask: 0.417
Last Trade Time: 7:58:04 PM EDT
Total Trades: 10,320
Potential here is quite large and transformative in more than a few areas. fda seems quite cooperative now too which is quite unusual.
Jun-30-23 12:42PM
Aethlon Medical, Inc. (NASDAQ:AEMD) Q4 2023 Earnings Call Transcript
(Insider Monkey)
-9.82%
Jun-28-23 04:15PM
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
(PR Newswire)
+7.85%
Jun-22-23 08:01AM
Aethlon Medical to Release Fourth Quarter and Year End Financial Results and Host Conference Call on June 28, 2023
(PR Newswire)
Jun-21-23 08:01AM
Aethlon Medical Announces Investigation of the Hemopurifier® for Use in Organ Transplantation
(PR Newswire)
Jun-14-23 08:01AM
Aethlon Medical to Participate in the Healthcare Virtual Conference Presented by Maxim Group and Hosted by M-Vest
(PR Newswire)
09:13AM
Loading…
Jun-08-23 09:13AM
AEMD: Maximizing R&D Spending to Facilitate Clinical Efforts, Advance Hemopurifier
(Zacks Small Cap Research)
Jun-01-23 03:51PM
Aethlon Medical to Present at the 13th Annual LD Micro Invitational
(PR Newswire)
Aethlon Medical to Release Fourth Quarter and Year End Financial Results and Host Conference Call on June 28, 2023 • PR Newswire (US) • 06/22/2023 12:01:00 PM
Short Interest 0.10M
Shs Float 22.70M
Shs Outstand 22.95M
Followers
|
234
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
18494
|
Created
|
11/19/04
|
Type
|
Free
|
Moderators |
At Aethlon Medical, we are a leading developer of immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses,
the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies.
The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure cloaks these targets from immune detection.
At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc.,
a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases.
Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical,
is focused on the discovery of exosomal biomarker candidates to diagnose and monitor life-threatening diseases.
The proprietary Enzyme-Linked Lectin-Specific Assay (ELLSA™) serves as a platform to isolate exosomal biomarkers from a wide-range of bodily fluids.
In preliminary studies, ELLSA™ demonstrated the ability to isolate exosomes from urine, which resulted in high-sensitivity detection of HIV-infection.
Specific to neurological disorders, Exosome Sciences discovered TauSome™, an exosomal biomarker that may be the first non-invasive candidate to
detect Chronic Traumatic Encephalopathy (CTE) in living individuals. In a study of former National Football League (NFL) players,
TauSome levels were found to be significantly higher as compared to athlete control subjects who participated in non-contact sports.
TauSome levels also correlated with cognitive decline based standardized tests of memory and psychomotor speed. Visit www.exosomesciences.com for additional details.
Time Magazine named the Hemopurifier® a "Top 25 Invention" and a "Remarkable Advance in Healthcare" based on its use in treating Ebola virus.
Emerging pathogens pose a significant threat to mankind. Of the hundreds of viral pathogens known to be infectious to man, only a few are addressed with
proven antiviral drug or vaccine therapies. Beyond the looming threat of bioterrorism, a proliferation of international travel, urban crowding and global warming
is expected to accelerate the emergence of future pandemics. In response, the U.S. Department of Health and Human Services (HHS) has established an initiative
to support platform technology medical countermeasures with broad-spectrum capabilities. Based on preclinical studies and human treatment experiences, the Aethlon Hemopurifier® defines this initiative.
To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV).
In the case of Ebola, a remarkable response to a single administration of Hemopurifier therapy (comatose physician with multiple organ failure at the time), led to
Time Magazine naming the Hemopurifier to be one of the "Top 25 Inventions" as well as one of the "Eleven Most Remarkable Advances in Healthcare."
Beyond human treatment experiences, pre-clinical Hemopurifier studies have validated the broad-spectrum capture of numerous viral threats.
These include: Chikungunya, Dengue and West Nile virus, as well as Vaccinia and Monkey pox, which serve as models for human Smallpox infection.
Specific to pandemic influenza threats, Aethlon has validated the capture of H5N1 avian flu, H1N1 swine flu, and the reconstructed 1918 influenza virus,
which represents a model for the strain of influenza that killed an estimated 50 million victims in 1918 and 1919. In vitro studies of other viral threats are ongoing.
https://coronavirus.jhu.edu/map.html
================================================================================================================================================================================
================================================================================================================================================================================
================================================================================================================================================================================
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |